AbbVie wins FDA approval for Venclexta-acalabrutinib combo in first-line chronic lymphocytic leukemia
Source: SeekingAlpha
2026-02-20 06:01:50 ET
More on AbbVie
- AbbVie: Dominating Immunology While Building Oncology Upside
- AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
- AbbVie: The Market Is Getting It Wrong
- China drug licensing deals surge nearly 10-fold in value since 2021
- AbbVie files lawsuit over selection of Botox for Medicare price negotiations
Read the full article on Seeking Alpha
For further details see:
AbbVie wins FDA approval for Venclexta-acalabrutinib combo in first-line chronic lymphocytic leukemia
AbbVie Inc.
NASDAQ: ABBV
ABBV Trading
-0.68% G/L:
$222.96 Last:
347,698 Volume:
$221.09 Open:
ABBV Latest News
March 13, 2026 01:36:56 pm
Concorde Financial Exits Howard Hughes Holdings, Developer of Large Sun Belt Communities
ABBV Stock Data
$396,361,630,803
1,749,710,786
N/A
2503
N/A
Pharmaceuticals
Healthcare
US
North Chicago
